Alphatec (ATEC)
(Delayed Data from NSDQ)
$5.49 USD
+0.27 (5.17%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $5.50 +0.01 (0.18%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.49 USD
+0.27 (5.17%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $5.50 +0.01 (0.18%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
Zacks News
3 Best Earnings Acceleration Stocks to Buy in a Strong Q4
by Tirthankar Chakraborty
With the advent of a strong fourth quarter, it's prudent to invest in stocks exhibiting solid earnings acceleration such as Argenx, Alphatec Holdings and Olin Corporation.
Alphatec (ATEC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -11.54% and 0.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Alphatec's (ATEC) New EOS Insight System to Boost Spine Care
by Zacks Equity Research
Alphatec (ATEC) announces the commercial launch of its EOS Insight, an end-to-end spine surgery platform powered by standardized EOSedge scans and artificial intelligence.
Strength Seen in ClearPoint Neuro (CLPT): Can Its 16.9% Jump Turn into More Strength?
by Zacks Equity Research
ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
OrthoPediatrics (KIDS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 28.57% and 7.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -32.14% and 0.27%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Alphatec (ATEC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -43.33% and 6.12%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Alphatec (ATEC) Surges 8.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Alphatec (ATEC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Alphatec (ATEC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -25% and 0.93%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Masimo (MASI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Alphatec (ATEC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Alphatec (ATEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -10% and 0.23%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Alphatec (ATEC) Soars 8.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Alphatec (ATEC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Alphatec (ATEC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -9.38% and 3.18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Alphatec (ATEC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Alphatec (ATEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Alphatec (ATEC) Could Rally 77%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Alphatec (ATEC) points to a 76.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Alphatec (ATEC) Soars 7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Alphatec (ATEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Alphatec (ATEC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -2.86% and 7.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Si-Bone (SIBN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Alphatec (ATEC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alphatec (ATEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alphatec (ATEC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -48.28% and 4.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Repro Med Systems, Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Repro Med Systems, Inc. (KRMD) delivered earnings and revenue surprises of 16.67% and 4.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Alphatec (ATEC): Can Its 12.1% Jump Turn into More Strength?
by Zacks Equity Research
Alphatec (ATEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
LENSAR, Inc. (LNSR) Moves 13.5% Higher: Will This Strength Last?
by Zacks Equity Research
LENSAR, Inc. (LNSR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.